Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1

Nicole E.B. Skinner; Matthew S. Wroblewski; Julie A. Kirihara; Gary L. Nelsestuen; Elizabeth R. Seaquist

doi:10.1007/s13300-015-0123-1

Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1

Nicole E.B. Skinner, Matthew S. Wroblewski, Julie A. Kirihara, Gary L. Nelsestuen, Elizabeth R. Seaquist

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Apolipoprotein C1 (ApoC1) is a component of multiple lipoproteins where it performs a variety of roles in lipid metabolism and transport. ApoC1 exists as both full-length and truncated isoforms. Truncation of ApoC1 has been postulated to result from the action of dipeptidyl peptidase-4 (DPP-4), the target of a new class of diabetes drugs that includes sitagliptin phosphate. In this study, we sought to determine if oral administration of sitagliptin altered the proportion of ApoC1 isoforms circulating in humans. Results indicated a dramatic change in ApoC1 truncation, consistent with a high level of DPP-4 inhibition by sitagliptin. Funding: University of Minnesota, Minneapolis, MN, USA.

Original language	English (US)
Pages (from-to)	395-401
Number of pages	7
Journal	Diabetes Therapy
Volume	6
Issue number	3
DOIs	https://doi.org/10.1007/s13300-015-0123-1
State	Published - Sep 26 2015

Bibliographical note

Publisher Copyright:
© 2015, The Author(s).

Keywords

Apolipoprotein C1
Mass spectrometry
Sitagliptin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1007/s13300-015-0123-1

OpenUrl availability

Full text

Cite this

@article{770e15cad7e74842af6f5612df54fdeb,

title = "Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1",

abstract = "Apolipoprotein C1 (ApoC1) is a component of multiple lipoproteins where it performs a variety of roles in lipid metabolism and transport. ApoC1 exists as both full-length and truncated isoforms. Truncation of ApoC1 has been postulated to result from the action of dipeptidyl peptidase-4 (DPP-4), the target of a new class of diabetes drugs that includes sitagliptin phosphate. In this study, we sought to determine if oral administration of sitagliptin altered the proportion of ApoC1 isoforms circulating in humans. Results indicated a dramatic change in ApoC1 truncation, consistent with a high level of DPP-4 inhibition by sitagliptin. Funding: University of Minnesota, Minneapolis, MN, USA.",

keywords = "Apolipoprotein C1, Mass spectrometry, Sitagliptin",

author = "Skinner, {Nicole E.B.} and Wroblewski, {Matthew S.} and Kirihara, {Julie A.} and Nelsestuen, {Gary L.} and Seaquist, {Elizabeth R.}",

note = "Publisher Copyright: {\textcopyright} 2015, The Author(s).",

year = "2015",

month = sep,

day = "26",

doi = "10.1007/s13300-015-0123-1",

language = "English (US)",

volume = "6",

pages = "395--401",

journal = "Diabetes Therapy",

issn = "1869-6953",

publisher = "Springer Publishing Company",

number = "3",

}

TY - JOUR

T1 - Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1

AU - Skinner, Nicole E.B.

AU - Wroblewski, Matthew S.

AU - Kirihara, Julie A.

AU - Nelsestuen, Gary L.

AU - Seaquist, Elizabeth R.

PY - 2015/9/26

Y1 - 2015/9/26

N2 - Apolipoprotein C1 (ApoC1) is a component of multiple lipoproteins where it performs a variety of roles in lipid metabolism and transport. ApoC1 exists as both full-length and truncated isoforms. Truncation of ApoC1 has been postulated to result from the action of dipeptidyl peptidase-4 (DPP-4), the target of a new class of diabetes drugs that includes sitagliptin phosphate. In this study, we sought to determine if oral administration of sitagliptin altered the proportion of ApoC1 isoforms circulating in humans. Results indicated a dramatic change in ApoC1 truncation, consistent with a high level of DPP-4 inhibition by sitagliptin. Funding: University of Minnesota, Minneapolis, MN, USA.

AB - Apolipoprotein C1 (ApoC1) is a component of multiple lipoproteins where it performs a variety of roles in lipid metabolism and transport. ApoC1 exists as both full-length and truncated isoforms. Truncation of ApoC1 has been postulated to result from the action of dipeptidyl peptidase-4 (DPP-4), the target of a new class of diabetes drugs that includes sitagliptin phosphate. In this study, we sought to determine if oral administration of sitagliptin altered the proportion of ApoC1 isoforms circulating in humans. Results indicated a dramatic change in ApoC1 truncation, consistent with a high level of DPP-4 inhibition by sitagliptin. Funding: University of Minnesota, Minneapolis, MN, USA.

KW - Apolipoprotein C1

KW - Mass spectrometry

KW - Sitagliptin

UR - http://www.scopus.com/inward/record.url?scp=84942323622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942323622&partnerID=8YFLogxK

U2 - 10.1007/s13300-015-0123-1

DO - 10.1007/s13300-015-0123-1

M3 - Article

C2 - 26198273

AN - SCOPUS:84942323622

SN - 1869-6953

VL - 6

SP - 395

EP - 401

JO - Diabetes Therapy

JF - Diabetes Therapy

IS - 3

ER -

Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this